WEBINAR ON DEMAND
Duration: 1 hour

The number of adults living with Alzheimer’s disease (AD) is expected to top 14 million by 2060—and not only is there no cure, current treatments aren’t successful and clinical trials to develop new therapeutic interventions keep failing. 

What’s holding back breakthroughs in finding new treatments? The cognitive scales used in most clinical trials aren’t ideal for the targeted patient cohorts, a significant reason that 98% of phase II and III clinical trials have failed. This webinar examines the need for more thoughtful approaches to cognitive testing in clinical drug trials for AD. After watching it, you’ll understand:

• Why popular assessment tools fail to accurately test cognitive functioning in AD
• Strategies for selecting the most reliable, valid and sensitive scales to assess cognitive functioning in clinical trials for AD, including when to choose analog versus digital testing
• How employing better endpoint measures can help advance AD research and drug development

SPEAKER

John Harrison, PhD
Chief Scientific Officer
Scottish Brain Sciences